Atopic dermatitis Trials in Pflugerville, United States
Conditions / Atopic dermatitis / Pflugerville, United States
Atopic dermatitis is a medical condition with active clinical research programs worldwide.
23 total trials for this combination
Showing top 10 of 23 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04178967 | Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE3 |
| NCT03435081 | A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE3 |
| NCT03587805 | Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND | COMPLETED | PHASE3 |
| NCT04392154 | Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) | COMPLETED | PHASE3 |
| NCT03568331 | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE) | COMPLETED | PHASE3 |
| NCT03540160 | Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) | TERMINATED | PHASE3 |
| NCT02975206 | Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis | COMPLETED | PHASE2 |
| NCT03160885 | Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) | COMPLETED | PHASE3 |
| NCT03559270 | A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis | TERMINATED | PHASE3 |
| NCT03607422 | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | COMPLETED | PHASE3 |